SEVERITY OF PRESENTING SYMPTOMS OF GASTRO-OESOPHAGEAL REFLUX DISEASE IN INFANTS AND THE EFFECTS OF TREATMENT WITH ESOMEPRAZOLE

(1) Clinical Development, AstraZeneca LP, Wilmington

(2) other, MassGeneral Hospital for Children, Boston, United States



This item was part of the PAEDIATRIC GASTROENTEROLOGY AND HEPATOLOGY II session at Gastro 2009 UEGW/WCOG London (17th UEGW)